{"id":"https://openalex.org/W3083321144","doi":"https://doi.org/10.1158/1538-7445.am2020-6637","title":"Abstract 6637: Inhibition of FGFR signaling by lenvatinib activates tumor interferon gamma signaling pathway and potentiates antitumor activity of anti-PD-1 antibody","display_name":"Abstract 6637: Inhibition of FGFR signaling by lenvatinib activates tumor interferon gamma signaling pathway and potentiates antitumor activity of anti-PD-1 antibody","alternate_titles":[],"publication_year":2020,"publication_date":"2020-08-15","ids":{"openalex":"https://openalex.org/W3083321144","doi":"https://doi.org/10.1158/1538-7445.am2020-6637","mag":"3083321144"},"language":"en","primary_location":{"id":"doi:10.1158/1538-7445.am2020-6637","doi":"https://doi.org/10.1158/1538-7445.am2020-6637","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2020-6637","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W3083321144"],"child_works_count":0,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5060408005","display_name":"Yusuke Adachi","orcid":"https://orcid.org/0000-0001-7700-5916","observed_orcids":["https://orcid.org/0000-0001-7700-5916"]},"institutions":[{"id":"https://openalex.org/I55881946","display_name":"Eisai (Japan)","ror":"https://ror.org/04vvh7p27","country_code":"JP","type":"company","lineage":["https://openalex.org/I55881946"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Yusuke Adachi","raw_affiliation_strings":["Eisai Co., Ltd., Tsukuba-shi, Ibaraki, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eisai Co., Ltd., Tsukuba-shi, Ibaraki, Japan","institution_ids":["https://openalex.org/I55881946"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100815486","display_name":"Hiroshi Kamiyama","orcid":"https://orcid.org/0009-0007-8010-8781","observed_orcids":["https://orcid.org/0009-0007-8010-8781"]},"institutions":[{"id":"https://openalex.org/I55881946","display_name":"Eisai (Japan)","ror":"https://ror.org/04vvh7p27","country_code":"JP","type":"company","lineage":["https://openalex.org/I55881946"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Hiroshi Kamiyama","raw_affiliation_strings":["Eisai Co., Ltd., Tsukuba-shi, Ibaraki, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eisai Co., Ltd., Tsukuba-shi, Ibaraki, Japan","institution_ids":["https://openalex.org/I55881946"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Kenji Ichikawa","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I55881946","display_name":"Eisai (Japan)","ror":"https://ror.org/04vvh7p27","country_code":"JP","type":"company","lineage":["https://openalex.org/I55881946"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Kenji Ichikawa","raw_affiliation_strings":["Eisai Co., Ltd., Tsukuba-shi, Ibaraki, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eisai Co., Ltd., Tsukuba-shi, Ibaraki, Japan","institution_ids":["https://openalex.org/I55881946"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5008447763","display_name":"Yoichi Ozawa","orcid":"https://orcid.org/0000-0002-3753-3703","observed_orcids":["https://orcid.org/0000-0002-3753-3703"]},"institutions":[{"id":"https://openalex.org/I55881946","display_name":"Eisai (Japan)","ror":"https://ror.org/04vvh7p27","country_code":"JP","type":"company","lineage":["https://openalex.org/I55881946"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Yoichi Ozawa","raw_affiliation_strings":["Eisai Co., Ltd., Tsukuba-shi, Ibaraki, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eisai Co., Ltd., Tsukuba-shi, Ibaraki, Japan","institution_ids":["https://openalex.org/I55881946"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5062679115","display_name":"Sayo Fukushima","orcid":"https://orcid.org/0000-0003-1149-255X","observed_orcids":["https://orcid.org/0000-0003-1149-255X"]},"institutions":[{"id":"https://openalex.org/I55881946","display_name":"Eisai (Japan)","ror":"https://ror.org/04vvh7p27","country_code":"JP","type":"company","lineage":["https://openalex.org/I55881946"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Sayo Fukushima","raw_affiliation_strings":["Eisai Co., Ltd., Tsukuba-shi, Ibaraki, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eisai Co., Ltd., Tsukuba-shi, Ibaraki, Japan","institution_ids":["https://openalex.org/I55881946"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5081046605","display_name":"Satoshi Goda","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I55881946","display_name":"Eisai (Japan)","ror":"https://ror.org/04vvh7p27","country_code":"JP","type":"company","lineage":["https://openalex.org/I55881946"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Satoshi Goda","raw_affiliation_strings":["Eisai Co., Ltd., Tsukuba-shi, Ibaraki, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eisai Co., Ltd., Tsukuba-shi, Ibaraki, Japan","institution_ids":["https://openalex.org/I55881946"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Shogo Yamaguchi","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I55881946","display_name":"Eisai (Japan)","ror":"https://ror.org/04vvh7p27","country_code":"JP","type":"company","lineage":["https://openalex.org/I55881946"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Shogo Yamaguchi","raw_affiliation_strings":["Eisai Co., Ltd., Tsukuba-shi, Ibaraki, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eisai Co., Ltd., Tsukuba-shi, Ibaraki, Japan","institution_ids":["https://openalex.org/I55881946"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5079712544","display_name":"Masahiro Matsuki","orcid":"https://orcid.org/0000-0001-9867-3702","observed_orcids":["https://orcid.org/0000-0001-9867-3702"]},"institutions":[{"id":"https://openalex.org/I55881946","display_name":"Eisai (Japan)","ror":"https://ror.org/04vvh7p27","country_code":"JP","type":"company","lineage":["https://openalex.org/I55881946"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Masahiro Matsuki","raw_affiliation_strings":["Eisai Co., Ltd., Tsukuba-shi, Ibaraki, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eisai Co., Ltd., Tsukuba-shi, Ibaraki, Japan","institution_ids":["https://openalex.org/I55881946"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5044623118","display_name":"Saori Watanabe Miyano","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I55881946","display_name":"Eisai (Japan)","ror":"https://ror.org/04vvh7p27","country_code":"JP","type":"company","lineage":["https://openalex.org/I55881946"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Saori Watanabe Miyano","raw_affiliation_strings":["Eisai Co., Ltd., Tsukuba-shi, Ibaraki, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eisai Co., Ltd., Tsukuba-shi, Ibaraki, Japan","institution_ids":["https://openalex.org/I55881946"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5079407472","display_name":"Akira Yokoi","orcid":"https://orcid.org/0000-0003-0789-5102","observed_orcids":["https://orcid.org/0000-0003-0789-5102","https://orcid.org/0009-0001-7869-2399"]},"institutions":[{"id":"https://openalex.org/I55881946","display_name":"Eisai (Japan)","ror":"https://ror.org/04vvh7p27","country_code":"JP","type":"company","lineage":["https://openalex.org/I55881946"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Akira Yokoi","raw_affiliation_strings":["Eisai Co., Ltd., Tsukuba-shi, Ibaraki, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eisai Co., Ltd., Tsukuba-shi, Ibaraki, Japan","institution_ids":["https://openalex.org/I55881946"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5039847095","display_name":"Yu Kato","orcid":"https://orcid.org/0000-0003-1662-6983","observed_orcids":["https://orcid.org/0000-0003-1662-6983"]},"institutions":[{"id":"https://openalex.org/I55881946","display_name":"Eisai (Japan)","ror":"https://ror.org/04vvh7p27","country_code":"JP","type":"company","lineage":["https://openalex.org/I55881946"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Yu Kato","raw_affiliation_strings":["Eisai Co., Ltd., Tsukuba-shi, Ibaraki, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eisai Co., Ltd., Tsukuba-shi, Ibaraki, Japan","institution_ids":["https://openalex.org/I55881946"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5003415756","display_name":"Yasuhiro Funahashi","orcid":"https://orcid.org/0000-0002-9299-0704","observed_orcids":["https://orcid.org/0000-0002-9299-0704"]},"institutions":[{"id":"https://openalex.org/I55881946","display_name":"Eisai (Japan)","ror":"https://ror.org/04vvh7p27","country_code":"JP","type":"company","lineage":["https://openalex.org/I55881946"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Yasuhiro Funahashi","raw_affiliation_strings":["Eisai Co., Ltd., Tsukuba-shi, Ibaraki, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eisai Co., Ltd., Tsukuba-shi, Ibaraki, Japan","institution_ids":["https://openalex.org/I55881946"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I55881946"],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"80","issue":"16_Supplement","first_page":"6637","last_page":"6637"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9945999979972839,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9945999979972839,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10422","display_name":"Angiogenesis and VEGF in Cancer","score":0.00139999995008111,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12287","display_name":"Fibroblast Growth Factor Research","score":0.0010000000474974513,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/lenvatinib","display_name":"lenvatinib","score":0.9990000128746033},{"id":"https://openalex.org/keywords/fgfr-signaling","display_name":"FGFR signaling","score":0.7319999933242798},{"id":"https://openalex.org/keywords/interferon-gamma-signaling","display_name":"interferon-gamma signaling","score":0.8529999852180481},{"id":"https://openalex.org/keywords/anti-pd-1-therapy","display_name":"anti-PD-1 therapy","score":0.8690000176429749},{"id":"https://openalex.org/keywords/anti-pd-1-antibody","display_name":"anti-PD-1","score":0.9010000228881836},{"id":"https://openalex.org/keywords/renal-cell-carcinoma","display_name":"renal cell carcinoma","score":0.7459999918937683},{"id":"https://openalex.org/keywords/axitinib","display_name":"axitinib","score":0.6790000200271606},{"id":"https://openalex.org/keywords/vegf-inhibition","display_name":"VEGF inhibition","score":0.7409999966621399},{"id":"https://openalex.org/keywords/pd-l1-expression","display_name":"PD-L1 expression","score":0.7059999704360962},{"id":"https://openalex.org/keywords/stat1-phosphorylation","display_name":"STAT1 phosphorylation","score":0.9570000171661377},{"id":"https://openalex.org/keywords/socs1","display_name":"SOCS1","score":0.9160000085830688},{"id":"https://openalex.org/keywords/jak-stat-signaling","display_name":"JAK/STAT signaling","score":0.9319999814033508},{"id":"https://openalex.org/keywords/tumor-microenvironment","display_name":"tumor microenvironment","score":0.6890000104904175},{"id":"https://openalex.org/keywords/combination-immunotherapy","display_name":"combination immunotherapy","score":0.7390000224113464},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitors","display_name":"immune checkpoint inhibitors","score":0.6380000114440918},{"id":"https://openalex.org/keywords/tyrosine-kinase-inhibitors","display_name":"tyrosine kinase inhibitors","score":0.6299999952316284},{"id":"https://openalex.org/keywords/endometrial-cancer","display_name":"endometrial cancer","score":0.5979999899864197}],"concepts":[{"id":"https://openalex.org/C2776264508","wikidata":"https://www.wikidata.org/wiki/Q6523413","display_name":"Lenvatinib","level":4,"score":0.8300824165344238},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.6837567090988159},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5320438146591187},{"id":"https://openalex.org/C62478195","wikidata":"https://www.wikidata.org/wiki/Q828130","display_name":"Signal transduction","level":2,"score":0.46934497356414795},{"id":"https://openalex.org/C101544691","wikidata":"https://www.wikidata.org/wiki/Q420511","display_name":"Receptor tyrosine kinase","level":3,"score":0.4617588222026825},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.420159250497818},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.2893844544887543},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.2771769165992737},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.24429717659950256},{"id":"https://openalex.org/C2778695046","wikidata":"https://www.wikidata.org/wiki/Q421136","display_name":"Sorafenib","level":3,"score":0.14565116167068481},{"id":"https://openalex.org/C95444343","wikidata":"https://www.wikidata.org/wiki/Q7141","display_name":"Cell biology","level":1,"score":0.07412603497505188},{"id":"https://openalex.org/C2778019345","wikidata":"https://www.wikidata.org/wiki/Q1148337","display_name":"Hepatocellular carcinoma","level":2,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1538-7445.am2020-6637","doi":"https://doi.org/10.1158/1538-7445.am2020-6637","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2020-6637","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9537000060081482,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2955048171","https://openalex.org/W3212668399","https://openalex.org/W2740838549","https://openalex.org/W4407849807","https://openalex.org/W4256439161","https://openalex.org/W2917680953","https://openalex.org/W2588754879","https://openalex.org/W4282982949","https://openalex.org/W3083419267","https://openalex.org/W4362595567"],"abstract_inverted_index":{"Abstract":[0],"Background:":[1],"Lenvatinib":[2,57],"mesilate":[3],"(LEN)":[4],"is":[5,60,71],"an":[6,173],"oral":[7],"multiple":[8],"receptor":[9],"tyrosine":[10],"kinase":[11,18],"(RTK)":[12],"inhibitor":[13,207,420],"that":[14,70,337],"selectively":[15],"inhibits":[16],"the":[17,39,80,110,136,154,219,269,272,294,309,327,344,367,383,479,483],"activity":[19,117,137,185,386,413,471],"of":[20,41,48,66,94,106,112,118,133,138,186,189,274,311,316,321,339,346,361,374,389,396,408,411,414,457,472,478,482],"VEGFR1-3,":[21],"in":[22,79,96,143,165,218,230,252,326,352,399,421,426],"addition":[23],"to":[24],"other":[25],"proangiogenic":[26],"and":[27,35,82,109,140,159,168,205,244,248,255,264,276,287,304,307,333,349,355,376,418,468,493],"oncogenic":[28],"pathway-related":[29],"RTKs":[30],"including":[31],"FGFR1-4;":[32],"PDGFR\u03b1;":[33],"KIT;":[34],"RET.":[36],"To":[37],"improve":[38],"efficacy":[40],"immune":[42],"checkpoint":[43],"inhibitors":[44,52],"(ICI),":[45],"combination":[46,89,187,273,400,422],"treatments":[47],"ICI":[49],"plus":[50,58,196,215,289],"anti-angiogenic":[51],"are":[53,90,123],"currently":[54],"under":[55],"investigation.":[56],"pembrolizumab":[59],"approved":[61],"for":[62,486],"2nd":[63],"line":[64],"treatment":[65,188,286,300,365],"advanced":[67],"endometrial":[68],"carcinoma":[69,148],"not":[72],"microsatellite":[73],"instability-high":[74],"or":[75,233,240],"mismatch":[76],"repair":[77],"deficient":[78],"US,":[81],"several":[83],"Ph3":[84],"clinical":[85],"trials":[86],"with":[87,393,401,423],"this":[88,128],"ongoing.":[91],"Immunosuppressive":[92],"roles":[93],"VEGF":[95],"tumor":[97,225,231,253,281,463],"microenvironment":[98],"have":[99],"been":[100],"well":[101],"studied;":[102],"however,":[103],"immunomodulatory":[104],"effects":[105],"FGFR":[107,113,157,179,243,340,362,377,419,458],"signaling":[108,158,163,246,341,369,378,398,459,466],"effect":[111],"inhibition":[114,373,395],"on":[115,175],"antitumor":[116,184,385,412,470],"anti-PD-1":[119,473],"antibody":[120,474],"(PD-1":[121],"Ab)":[122],"still":[124],"largely":[125],"unknown.":[126],"In":[127,268,293],"study,":[129],"we":[130],"investigated":[131],"mechanism":[132],"action":[134],"underlying":[135],"LEN":[139,171,190,275,299,364,380,415],"PD-1":[141,197,216,277,290,402,424],"blockade":[142,425],"syngeneic":[144],"mouse":[145],"renal":[146],"cell":[147,358],"(RCC)":[149],"model.":[150,226],"We":[151,182],"also":[152,324],"explored":[153],"relationship":[155],"between":[156],"interferon":[160,464],"(IFN)":[161],"\u03b3":[162],"pathway":[164,177,342,391,467],"cancer":[166,357],"cells,":[167],"examined":[169,183],"whether":[170],"has":[172],"impact":[174],"IFN\u03b3":[176,245,368,390],"by":[178,238,260,329,363,379,460],"inhibition.":[180],"Methods:":[181],"at":[191,199,210],"10":[192,200,211],"mg/kg":[193,201,212],"(po,":[194,213],"qd)":[195],"Ab":[198,217,278,291],"(ip,":[202],"twice":[203],"weekly)":[204],"VEGF-selective":[206],"axitinib":[208],"(Axi)":[209],"bid)":[214],"RAG":[220,270,353],"(murine":[221],"RCC":[222],"cell)":[223],"subcutaneous":[224],"Gene":[227],"expression":[228,306,310,320,351],"profile":[229],"tissues":[232,254],"cultured":[234,256],"cells":[235,257,354],"was":[236,323],"analyzed":[237,259],"qRT-PCR":[239,334],"RNA":[241],"seq.":[242],"pathways":[247],"their":[249],"downstream":[250],"molecules":[251],"were":[258],"western":[261],"blot":[262],"(WB)":[263],"immunofluorescence":[265],"(IF).":[266],"Results:":[267],"model,":[271],"showed":[279],"greater":[280,384],"response":[282],"than":[283],"each":[284],"single":[285,394],"Axi":[288],"combination.":[292],"tumors,":[295],"WB":[296,332],"analysis":[297],"revealed":[298],"increased":[301],"STAT1":[302],"phosphorylation":[303],"PD-L1":[305,322,348],"decreased":[308],"SOCS1,":[312],"a":[313],"suppressor":[314],"molecule":[315],"JAK-STAT":[317],"signaling.":[318],"Increased":[319],"observed":[325],"tumors":[328],"IF":[330],"analysis.":[331],"analyses":[335],"elucidated":[336],"activation":[338,388],"inhibited":[343],"induction":[345],"B2M,":[347],"CXCL10":[350],"human":[356],"lines.":[359],"Inhibition":[360,456],"reactivated":[366],"pathway.":[370],"Conclusion:":[371],"Dual":[372],"VEGFR":[375,397,417],"may":[381],"exert":[382],"via":[387],"compared":[392],"Ab.":[403],"These":[404],"results":[405],"provide":[406],"one":[407],"unique":[409],"mechanisms":[410],"as":[416],"preclinical":[427],"models.":[428],"Citation":[429],"Format:":[430],"Yusuke":[431],"Adachi,":[432],"Hiroshi":[433],"Kamiyama,":[434],"Kenji":[435],"Ichikawa,":[436],"Yoichi":[437],"Ozawa,":[438],"Sayo":[439],"Fukushima,":[440],"Satoshi":[441],"Goda,":[442],"Shogo":[443],"Yamaguchi,":[444],"Masahiro":[445],"Matsuki,":[446],"Saori":[447],"Watanabe":[448],"Miyano,":[449],"Akira":[450],"Yokoi,":[451],"Yu":[452],"Kato,":[453],"Yasuhiro":[454],"Funahashi.":[455],"lenvatinib":[461],"activates":[462],"gamma":[465],"potentiates":[469],"[abstract].":[475],"In:":[476],"Proceedings":[477],"Annual":[480],"Meeting":[481],"American":[484],"Association":[485],"Cancer":[487,499],"Research":[488],"2020;":[489],"2020":[490],"Apr":[491],"27-28":[492],"Jun":[494],"22-24.":[495],"Philadelphia":[496],"(PA):":[497],"AACR;":[498],"Res":[500],"2020;80(16":[501],"Suppl):Abstract":[502],"nr":[503],"6637.":[504]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W3083321144","counts_by_year":[{"year":2026,"cited_by_count":1}],"updated_date":"2026-11-07T11:25:07.637180","created_date":"2020-09-11T00:00:00"}
